SACUTAN 24/26 TABLETS

SACUTAN 24/26 TABLETS is a medication that combines two active ingredients: sacubitril and valsartan. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker (ARB). This combination works synergistically to manage certain cardiovascular conditions.

Uses:

1. Heart Failure:
   • SACUTAN is indicated for the treatment of chronic heart failure (NYHA Class II-IV) in adults to reduce the risk of cardiovascular death and hospitalization.

Side Effects:

Common side effects may include:

• Hypotension (low blood pressure)
• Elevated levels of potassium in the blood
• Dizziness or lightheadedness
• Cough
• Kidney problems

Serious side effects may include:

• Angioedema (swelling of the deeper layers of the skin)
• Impaired renal function
• Hypotension, especially in patients with volume depletion

When Not to Use:

1. Pregnancy:
   • SACUTAN is contraindicated in pregnancy. It can cause fetal harm, and women who become pregnant should discontinue the medication as soon as possible.
2. Hypersensitivity:
   • Individuals with a history of hypersensitivity to sacubitril or valsartan should not use SACUTAN.
3. Use with Aliskiren:
   • SACUTAN should not be co-administered with aliskiren in patients with diabetes due to the increased risk of renal impairment, hypotension, and hyperkalemia.
4. Severe Hepatic Impairment:
   • SACUTAN is not recommended in patients with severe hepatic impairment.

Precautions and Warnings:

• Renal Impairment:
  • Monitoring of renal function is essential, especially in patients with renal impairment or those concomitantly taking other medications affecting the renin-angiotensin-aldosterone system.
• Hypotension:
  • Patients may experience symptomatic hypotension, particularly after the first dose. Blood pressure should be monitored regularly.
• Hyperkalemia:
  • Monitoring of potassium levels is advised, especially in patients at risk of hyperkalemia.

It is crucial to consult with a healthcare professional before starting or discontinuing SACUTAN, as individual patient circumstances may vary. This information is not exhaustive, and healthcare providers should refer to the prescribing information for a comprehensive understanding of the medication.